A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Latest Information Update: 01 Mar 2023
At a glance
- Drugs BMS-986226 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; DTaP vaccine
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 31 Jan 2023 Status changed from completed to discontinued.
- 28 Sep 2022 This trial has been discontinued in Spain (Date of the global end of the trial : 20-Dec-2021), according to European Clinical Trials Database record.
- 12 Jun 2020 This trial is suspended in Spain, according to European Clinical Trials Database record.